Skip to content

Multigene Analysis of Tissue-Specific Biomarkers (Tissue-Specific Cancer Risk Panel)

Published: August 9, 2026Updated: August 16, 2026

This test evaluates genetic markers linked to certain cancers by analyzing tissue-specific proteins or peptides in your blood. It helps assess potential inherited risks for specific types of cancer based on your genetic profile.

Quick summary

["This test may help identify inherited cancer risks by detecting biomarkers tied to tissue-specific cancers."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
105593-8
Short code
RCC multigene analysis Tiss
Synonyms
RCC multigene analysis Tiss
Category
chemistry
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
molgen
CPT
86038
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

What This Test Measures

The test analyzes a panel of biomarkers that reflect genetic predispositions for cancers affecting specific tissues, such as breast, prostate, or gastrointestinal tissues. These biomarkers are proteins or peptides that may be elevated or altered in individuals with certain inherited cancer syndromes.

Why It Might Be Ordered

Your healthcare provider may recommend this test if you have a family history of certain cancers, a genetic predisposition test was positive, or you’re at higher risk due to lifestyle or other factors. It’s not a routine screening test for all cancers but can provide targeted insights for prevention or monitoring.

Sample Collection and Preparation

A blood sample is typically drawn from a vein in your arm. The blood is processed to isolate the tissue-specific biomarkers, which are then analyzed using advanced laboratory techniques to detect their presence and levels.

How Results Are Interpreted

Results are compared to known reference ranges for these biomarkers. Elevated or abnormal levels may indicate an increased risk for specific cancers, but they do not confirm a diagnosis. Your healthcare provider will discuss findings in the context of your medical history and family background.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

◆Associated findings1

Short name

Tissue-Specific Cancer Risk Test

Frequently asked questions

What does this test involve?
This test involves analyzing specific proteins or peptides in your blood that may reflect genetic risks for certain cancers. It’s not a general cancer screening but focuses on tissue-specific biomarkers tied to inherited conditions.
How long does it take to get results?
Results are typically available within 1 to 2 weeks after the sample is processed, depending on laboratory workflows. Your healthcare provider will contact you once results are ready.
Can this test replace other cancer screenings?
No, this test is not a substitute for standard cancer screenings (like mammograms, colonoscopies, or PSA tests). It’s used alongside other tests to provide additional insights into tissue-specific risks based on genetic factors.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy